Rakesh Verma, PhD (Medical Oncology)
Rakesh Verma, PhD (Medical Oncology)
Verified email at aya.yale.edu
Cited by
Cited by
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
R Das, R Verma, M Sznol, CS Boddupalli, SN Gettinger, H Kluger, ...
The Journal of Immunology 194 (3), 950-959, 2015
Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation
S Nair, CS Boddupalli, R Verma, J Liu, R Yang, GM Pastores, PK Mistry, ...
Blood 125 (8), 1256-1271, 2015
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells
CS Boddupalli, N Bar, K Kadaveru, M Krauthammer, N Pornputtapong, ...
JCI insight 1 (21), 2016
Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice
R Verma
Nature Medicine. 2016 November ; 22(11): 1351–1357 (https://www.ncbi.nlm.nih …, 2016
Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice
R Verma
Nature Medicine 22, 22, 1351–1357 (2016), 2016
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
DMV Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru ...
Blood 125 (26), 4042-51, 2015
Significantly reduced regulatory T cell population in patients with untreated multiple myeloma
R Gupta, P Ganeshan, M Hakim, R Verma, A Sharma, L Kumar
Leukemia research 35 (7), 874-878, 2011
ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells
CS Boddupalli, S Nair, SM Gray, HN Nowyhed, R Verma, JA Gibson, ...
The Journal of clinical investigation 126 (10), 3905-3916, 2016
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
A Naing, DJ Wong, JR Infante, WM Korn, R Aljumaily, KP Papadopoulos, ...
The Lancet Oncology, 2019
Complete response after autologous stem cell transplant in multiple myeloma
L Kumar, N Iqbal, A Mookerjee, RK Verma, OD Sharma, A Batra, ...
Cancer medicine 3 (4), 939-946, 2014
Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial
AR Branagan, E Duffy, RA Albrecht, DL Cooper, S Seropian, TL Parker, ...
Clinical Lymphoma Myeloma and Leukemia 17 (5), 296-304. e2, 2017
Erythropoietin-directed erythropoiesis depends on serpin inhibition of erythroblast lysosomal cathepsins
A Dev, SM Byrne, R Verma, PG Ashton-Rickardt, DM Wojchowski
Journal of Experimental Medicine 210 (2), 225-232, 2013
Defining an EPOR-regulated transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO-dependent erythroblast formation
S Singh, A Dev, R Verma, A Pradeep, P Sathyanarayana, JM Green, ...
PloS one 7 (7), e38530, 2012
Recent advances in the management of multiple myeloma
L Kumar, R Verma, VR Radhakrishnan
The National medical journal of India 23 (4), 210-218, 2010
RHEX, a novel regulator of human erythroid progenitor cell expansion and erythroblast development
R Verma, S Su, DJ McCrann, JM Green, K Leu, PR Young, PJ Schatz, ...
Journal of Experimental Medicine 211 (9), 1715-1722, 2014
Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles
S Singh, R Verma, A Pradeep, K Leu, RB Mortensen, PR Young, M Oyasu, ...
PloS one 7 (1), e29064, 2012
Two dose series of high-dose influenza vaccine is associated with longer duration of serologic immunity in patients with plasma cell disorders
A Branagan, E Duffy, C Foster, R Verma, L Zhang, G Gan, F Li, ...
Blood 130 (Suppl 1), 438-438, 2017
Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
R Verma, Z Mai, M Xu, L Zhang, K Dhodapkar, MV Dhodapkar
Blood 126 (23), 913-913, 2015
A dimeric peptide with erythropoiesis-stimulating activity uniquely affects erythropoietin receptor ligation and cell surface expression
R Verma, JM Green, PJ Schatz, DM Wojchowski
Experimental hematology 44 (8), 765-769. e1, 2016
Comparison of intermittent and continuous dosing regimens of pomalidomide in relapsed/refractory myeloma: results of a phase II randomized trial
K Sehgal, MH Kocoglu, Y Deng, R Verma, L Zhang, DL Cooper, X Yao, ...
Blood 122 (21), 3205-3205, 2013
The system can't perform the operation now. Try again later.
Articles 1–20